Drug company is suspended from UK industry body after “deception on a grand scale”BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3574 (Published 27 June 2016) Cite this as: BMJ 2016;353:i3574
- Adrian O’Dowd
The UK subsidiary of a prominent Japanese drug firm has had its membership of the United Kingdom’s industry representative body suspended after what has been described as “deception on a grand scale.”
The Association of the British Pharmaceutical Industry’s one year suspension of Astellas UK, from 24 June, was made because of serious breaches of the association’s code of practice that related to covert attempts to market prostate cancer drugs to doctors.
The decision came after a complaint about an advisory board meeting that was held in Milan in February 2014 and was ruled to be in breach of the code, including of clause 2, which deals with actions likely to bring discredit on, or …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial